Immune Cell Gene Study in Triple-Negative Breast Cancer
Studies immune cell receptor genes in people with triple-negative breast cancer.
Plain-language title generated from the registry record
Registry title: Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
Key facts
- Where
- Thessaloniki, GreeceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with a confirmed diagnosis of triple-negative breast cancer (TNBC).
- Sex
- Women only.
- Disease stage
- Confirmed triple-negative breast cancer (TNBC).
Read by machine on 9 November 2026.
Where in Greece
- Institute of Applied BiosciencesThessaloniki, GreeceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Applied Biosciences
- Trial code
- NCT06646263
- Record updated
- 17 October 2024
- Original description
This project introduces a novel methodology for the in-depth immunogenetic characterization of the TR gene repertoire in solid tumors, holding the promise to offer unprecedented insights into the TR anti-tumor specificity and the prognostic/predictive value of TR gene repertoire signatures.Read full original descriptionShow less
Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
This project introduces a novel methodology for the in-depth immunogenetic characterization of the TR gene repertoire in solid tumors, holding the promise to offer unprecedented insights into the TR anti-tumor specificity and the prognostic/predictive value of TR gene repertoire signatures.
Inclusion: Confirmed TNBC diagnosis.
Exclusion: -.